Jackson Walker L.L.P. recently assisted Sun BioPharma, Inc. in connection with its $2.3 million bridge financing transaction (consisting of convertible promissory notes and warrants) to existing stockholders.

Florida-based Sun BioPharma is developing a drug compound to treat pancreatic cancer based on technology licensed from The University of Florida. The funds will allow Sun BioPharma to finish the preclinical work necessary to commence a Phase IA/IB trial in 33 patients in Australia.

A Jackson Walker team led by Jeff Harder, with assistance from Joe Fonlon and Theresa Breslin represented Sun BioPharma in the transaction. Attorneys in Jackson Walker’s Corporate & Securities practice group have extensive experience representing clients in a wide variety of complex corporate matters. In addition, the firm’s attorneys have an advanced understanding of the unique and sophisticated needs of clients in the Biotech, MedTech and Life Sciences sector.